Clinical Trials

Inovio Pharmaceuticals, Inc. announced preliminary results from the expanded stage of its phase I study, EBOV-001. The expanded study examined different regimens of its Ebola DNA vaccine INO-4201 using intradermal (skin) administration. The results across both...

Cytori Therapeutics, Inc. announced that the U.S. FDA has approved an IDE for a pilot clinical trial to evaluate Cytori Cell Therapy™ in patients with thermal burn injury. This trial, named the RELIEF trial, is a...

Kiadis Pharma N.V. , a clinical stage biopharmaceutical company developing innovative T-cell immunotherapy treatments for blood cancers and inherited blood disorders announces that it has obtained regulatory approval from the national authority in Belgium. The FAGG,...

Selvita , a clinical stage drug discovery and development company focused on innovative medicines for patients with blood cancers, announced that the first patient was dosed with SEL24 in a Phase I/II clinical trial, for acute myeloid leukemia (AML)....

LEO Pharma today announced positive results from a Phase 2b dose-ranging efficacy and safety study of tralokinumab in adult patients with moderate to severe atopic dermatitis (AD), a serious and chronic form of eczema.  Tralokinumab is...

Inovio Pharmaceuticals, Inc. announced that Dr. David B. Weiner, Inovio’s co-founder, presented positive clinical data on Inovio’s DNA-based vaccines against MERS (GLS-5300) and Zika (GLS-5700) at the Coalition for Epidemic Preparedness Innovation (CEPI)’s 1st Scientific Meeting on “Vaccines Against...

DelMar Pharmaceuticals, Inc , a biopharmaceutical company focused on the development and commercialization of new cancer therapies. Announced that patient dosing has commenced in a Phase 2 clinical study of its investigational drug VAL-083 (dianhydrogalactitol) for...